Vaccines for lung cancer

Ronan J. Kelly

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Active immunotherapy alone may be insufficient to treat advanced disease but may be a viable option in the adjuvant setting. Response evaluation criteria in solid tumors may not satisfy the criteria for judging effective immunotherapy. Immune-related response criteria will be needed to accurately assess objective responses to immunotherapeutics. Mucin 1, TGF-b and EGF vaccines may be useful in the locally advanced and metastatic setting. Melanoma-associated antigen-A3 vaccine is currently being investigated in patients with completely resected stage IB-IIIA non-small-cell lung cancer. Predictive gene signatures may help to select patients that will likely benefit from a certain immunotherapy.

Original languageEnglish (US)
Title of host publicationTargeted Therapies for Non-Small-Cell Lung Cancer
PublisherFuture Medicine Ltd.
Pages89-101
Number of pages13
ISBN (Electronic)9781780840468
ISBN (Print)9781780841236
DOIs
StatePublished - Oct 1 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Vaccines for lung cancer'. Together they form a unique fingerprint.

Cite this